Drugs / BE CAR7 T cells
BE CAR7 T cells
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05397184 | Apr 2022 → Apr 2024 | T-cell acute lymphoblastic leukemia | Great Ormond Street Hospital for Children NHS Foundation Trust | Unknown | No outcome recorded |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | BE CAR7 T cells | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05397184 ↗ |
| Known as | BE CAR-7 | “These 'ready-made' CAR T cells have been made using a new technique called CRISPR base editing to modify them DNA code and have been given the name BE CAR-7.” NCT05397184 ↗ |
| Known as | BE752TBCCLCAR7PBL | “Cryopreserved BE CAR7 T cells (BE752TBCCLCAR7PBL)” NCT05397184 ↗ |
| Action | Deplete | “changed so they can kill other T cells, including leukaemia cells” NCT05397184 ↗ |
| Modality | Cell therapy | “The cell therapy is made from white blood cells (T cells) collected from a healthy donor” NCT05397184 ↗ |
| Route | Intravenous | “Single-dose intravenous infusion” NCT05397184 ↗ |